Pages that link to "Q46055776"
The following pages link to Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics (Q46055776):
Displaying 50 items.
- Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugs (Q26774831) (← links)
- Variable expression of CYP and Pgp genes in the human small intestine (Q28196397) (← links)
- Splenda alters gut microflora and increases intestinal p-glycoprotein and cytochrome p-450 in male rats (Q28570040) (← links)
- Pharmacokinetics and metabolism of a sulphamide NK2 antagonist in rat, dog and human (Q31420878) (← links)
- Secretory transport of p-aminohippuric acid across intestinal epithelial cells in Caco-2 cells and isolated intestinal tissue (Q32019218) (← links)
- Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. (Q32079834) (← links)
- Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport (Q32079916) (← links)
- Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction (Q33148996) (← links)
- Improving the oral bioavailability of beneficial polyphenols through designed synergies. (Q33646033) (← links)
- Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration (Q33692808) (← links)
- Pharmacokinetics and metabolism in early drug discovery (Q33695719) (← links)
- Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells (Q33807628) (← links)
- Virtual screening of intestinal drug permeability (Q33852942) (← links)
- Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors (Q33865979) (← links)
- Multixenobiotic resistance as a cellular defense mechanism in aquatic organisms (Q33905646) (← links)
- Antibiotic efflux pumps (Q33954740) (← links)
- Can multidrug resistance mechanisms be modified? (Q34022485) (← links)
- P-glycoprotein and bioavailability-implication of polymorphism (Q34093099) (← links)
- Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine (Q34106544) (← links)
- P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions (Q34171741) (← links)
- The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein (Q34235311) (← links)
- Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems (Q34285667) (← links)
- Dedication to professor Leslie Z. Benet: 50 years of scientific excellence and still going strong! (Q34289184) (← links)
- Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation (Q34332261) (← links)
- The drug efflux-metabolism alliance: biochemical aspects. (Q34384318) (← links)
- Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers (Q34570866) (← links)
- Prediction of intestinal permeability (Q34581541) (← links)
- The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? (Q34615575) (← links)
- Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo (Q34634236) (← links)
- General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs (Q34656231) (← links)
- How important are gender differences in pharmacokinetics? (Q34660699) (← links)
- A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals (Q34665881) (← links)
- Mechanisms of clinically relevant drug interactions associated with tacrolimus (Q34791985) (← links)
- Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals (Q35000765) (← links)
- The biochemistry and medical significance of the flavonoids (Q35009698) (← links)
- Role of P-glycoprotein in pharmacokinetics: clinical implications (Q35029495) (← links)
- The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy (Q35073349) (← links)
- Predicting oral absorption and bioavailability (Q35140074) (← links)
- Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs (Q35164664) (← links)
- Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor (Q35196297) (← links)
- Early factors in successful anti-HIV treatment (Q35207282) (← links)
- Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome. (Q35547031) (← links)
- ABC of oral bioavailability: transporters as gatekeepers in the gut. (Q35591517) (← links)
- The MDR1 (ABCB1) gene polymorphism and its clinical implications (Q35817004) (← links)
- Oral contraception does not alter single dose saquinavir pharmacokinetics in women (Q35825971) (← links)
- Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms (Q35876954) (← links)
- Pharmacokinetics of proton pump inhibitors in children (Q36116456) (← links)
- An examination of the blood-brain barrier in health and disease (Q36143960) (← links)
- Pharmacokinetic considerations relating to tacrolimus dosing in the elderly. (Q36204404) (← links)
- Drug interactions with antiretrovirals (Q36223755) (← links)